PDS Biotechnology Files 8-K
Ticker: PDSB · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, biotechnology
TL;DR
PDS Biotech filed a routine 8-K on 8/25/25. No major news.
AI Summary
PDS Biotechnology Corporation filed an 8-K on August 25, 2025, reporting other events and financial statements. The company, formerly known as Edge Therapeutics, Inc., is incorporated in Delaware and headquartered in Princeton, NJ. This filing does not appear to disclose specific new events or financial figures beyond routine reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by PDS Biotechnology Corp. Investors should review the full document for any specific disclosures that may impact the company's operations or financial standing.
Risk Assessment
Risk Level: low — The filing appears to be a standard 8-K for reporting purposes and does not contain information about significant new events, risks, or financial changes.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- Edge Therapeutics, Inc. (company) — Former company name
- August 25, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Princeton, NJ (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for PDS Biotechnology Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of August 25, 2025.
When was PDS Biotechnology Corporation's previous name?
PDS Biotechnology Corporation's former company name was Edge Therapeutics, Inc., with a date of name change on September 11, 2009.
Where are PDS Biotechnology Corporation's principal executive offices located?
PDS Biotechnology Corporation's principal executive offices are located at 303A College Road East, Princeton, NJ 08540.
What is the SEC file number for PDS Biotechnology Corporation?
The SEC file number for PDS Biotechnology Corporation is 001-37568.
What is the SIC code for PDS Biotechnology Corporation?
The Standard Industrial Classification (SIC) code for PDS Biotechnology Corporation is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-08-25 08:35:49
Key Financial Figures
- $0.00033 — ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M
Filing Documents
- ef20054394_8k.htm (8-K) — 26KB
- ef20054394_ex99-1.htm (EX-99.1) — 21KB
- image00001.jpg (GRAPHIC) — 263KB
- 0001140361-25-032433.txt ( ) — 540KB
- pdsb-20250825.xsd (EX-101.SCH) — 4KB
- pdsb-20250825_lab.xml (EX-101.LAB) — 21KB
- pdsb-20250825_pre.xml (EX-101.PRE) — 16KB
- ef20054394_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On August 25, 2025, PDS Biotechnology Corporation issued a press release announcing final topline survival data from its VERSATILE-002 Phase 2 clinical trial. VERSATILE-002 evaluated PDS0101 (Versamune HPV) + Keytruda (pembrolizumab) in patients with HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated August 25, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: August 25, 2025 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer